Lorlatinib was tested in a phase I trial in 54 pretreated or treatment-naïve ALK- (N = 41) or ROS-1 (N = 12) positive NSCLC patients (11% treatment-naïve, 52% two or more previous TKIs, and 72% with BM). Here, ALK is linked to non-small cell lung carcinoma.